 |
The business
- Medical diagnostic pharmaceuticals for early, accurate diagnosis
of heart disease, circulatory disorders, lung disease, diseases
of the brain and cancer.
- Radiotherapy
products for the treatment of cancer.
Performance 2001*
| Sales |
Operating profit |
R&D expenditure |
Employees |
| £922 million, |
£241 million, |
£83 million, |
5,000 |
| up 13% |
up 10% |
up 10% |
|
*All results are stated before exceptional items
and goodwill amortisation and in UK GAAP. Growth rates are at constant
exchange.
Product portfolio
Sustained growth – new opportunities
Leading brands
|
New products |
Clinical pipeline |
X-ray
Omnipaque™ (1982)
Visipaque™ (1993) |
|
|
MRI
Omniscan™ (1992) |
|
Omniscan (angiography)
Helispin™ (lungs) |
Radiopharmaceutical imaging
Myoview™ (1994) |
DaTSCAN™ (2000)
Myoview (stress, 2001)
Neospect ™ (2001) |
NC100668 (thrombosis) |
| Ultrasound |
Optison™ (2001) |
Sonazoid™ (liver)
Sonazoid (heart perfusion) |
Radiotherapy
OncoSeed™ (1991)
Rapid Strand™ (1994) |
TheraSeed™ (2001)
EchoSeed™ (2001) |
Bexxar™ (Non-Hodgkin’s
Lymphoma) |
| |
|
Research pipeline
Parkinson’s Disease
Atherosclerosis
Alzheimer's Disease
F18 - PET
C13 - Spin Signal™
Targeted ultrasound |
For market information, see Health
Market Report.
Businesses at a glance continues on the
next page »
|
|
